Sun Pharma Advanced Research (SPARC) Fundamentals 2026 — P/E 4.5x, Revenue Analysis | SniperIQ
Sun Pharma Advanced Research (SPARC) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹6,939 Crore, trading at ₹213.95 on the BSE. This SniperIQ fundamentals page covers Sun Pharma Advanced Research's valuation (P/E 4.5x, P/B 5.2x), profitability (net margin 82.7%), revenue (₹1,879 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sun Pharma Advanced Research's market cap?
Sun Pharma Advanced Research (SPARC) has a market capitalization of approximately ₹6,939 Crore, trading at ₹213.95 on the BSE. Market cap moves with the live share price.
What is Sun Pharma Advanced Research's P/E ratio?
Sun Pharma Advanced Research's trailing twelve-month P/E ratio is 4.5x, with a price-to-book (P/B) of 5.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sun Pharma Advanced Research?
Sun Pharma Advanced Research runs a net profit margin of 82.7%, a gross margin of 94.7%, and an operating margin of 84.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sun Pharma Advanced Research generate?
Sun Pharma Advanced Research reported revenue of ₹1,879 Crore for fiscal year 2026, with net income of ₹1,553 Crore and earnings per share (EPS) of 47.86. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sun Pharma Advanced Research pay a dividend?
Sun Pharma Advanced Research does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Sun Pharma Advanced Research financially healthy?
Sun Pharma Advanced Research carries a debt-to-equity ratio of 0.42x and a current ratio of 2.47x, with a market beta of 0.54. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sun Pharma Advanced Research a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sun Pharma Advanced Research (SPARC) the key facts are: market cap ₹6,939 Crore, P/E 4.5x, revenue ₹1,879 Crore, 52-week range 108.2-289. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sun Pharma Advanced Research's full fundamentals live
Get Sun Pharma Advanced Research's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.